NovoSeven® RT was the first recombinant bypassing agent for congenital hemophilia with inhibitors and is the only rFVIIa approved across all age groups.1,2
Efficacy seen in Lusher et al3
Muscle bleeds
N=29
Joint bleeds
N=145
Efficacy seen in adept™24
All bleed locations
at 12 hours
N=69
One of the largest clinical trials conducted in patients with CHwI
Consistent efficacy seen in joint, target joint, mucocutaneous, muscle, and other bleeding episodes
98% effective bleed control in patients ≤18 years, based on real-world experience5
aIn patients with hemophilia A or B with inhibitors.3
bCalculation of 5 hours is based on 2.2 doses at 2-hour interval.
cFVIIa activity IU/mL.
Results of a prospective, randomized trial show the effectiveness of NovoSeven® RT. Percentage of patients with adequate hemostasis:7
The postoperative period: essential to surgical success
Adapted from Shapiro et al.7,d
dIn patients with hemophilia A or B with inhibitors. Actual length of postoperative period may vary.
Established safety profile
Pivotal studies show a low rate of thrombotic events.
Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.1 Thrombotic adverse reactions in pivotal clinical trials occurred in 0.2% of bleeding episodes in patients with congenital hemophilia with inhibitors.1,e
See Important Safety Information, including Boxed Warning.
eIn patients with congenital hemophilia.
Data from pivotal clinical trials1
Occurrence of thrombotic events
NovoSeven® RT is the only rFVIIa with clinical experience with Hemlibra®.
NovoSeven® RT was used safely in 61 patients CHAwI treating with Hemlibra in 3 separate pivotal trials: HAVEN 1, 2, and 4.9,10,f
180 bleeds were treated with NovoSeven® RT only in HAVEN 1
No SAEs, TMAs, or TEs were observed with use of NovoSeven® RT alone in HAVEN 1, 2, and 4
No new or unexpected safety concerns were observed with use of NovoSeven® RT in conjunction with Hemlibra
Two cases of TMA occurred in patients treating with Hemlibra while receiving FEIBA® and NovoSeven® RT. Simultaneous use of NovoSeven® RT and FEIBA should be avoided
MASAC recommends rFVIIa as a first option to treat acute bleeding episodes in patients with CHAwI on emicizumab—aPCC should be avoided if possible.9
These MASAC recommendations were created based in part on the safe use of NovoSeven® RT with Hemlibra® in 3 of the pivotal HAVEN clinical trials.9,10
MASAC=Medical and Scientific Advisory Council; rFVIIa=recombinant activated factor VII; SAE=serious adverse event; TMA=thrombotic microangiopathy; TE=thrombotic event.
fThe analysis included bleeding episodes in the HAVEN 1, HAVEN 2, and HAVEN 4 clinical trials for which patients with CHAwI on emicizumab prophylaxis (at the labeled dose) used rFVIIa. Initial individual dosing with rFVIIa, dosing intervals, and cumulative dosing were evaluated. All adverse events reported in each of the 3 trials, including available narratives, were assessed. The cutoff date for the data presented was September 8, 2017.
NovoSeven® RT is manufactured with safety in mind
NovoSeven® RT is not made from human serum or proteins. Recombinant manufacturing minimizes the possibility of viral contamination.1,12
Study designs
Randomized, double-blind, parallel group, international multicenter trial (Lusher, et al):
Results shown are from the 70 mcg/kg group.
Study involved patients with hemophilia A and B with and without an inhibitor (N=84). Patients were given NovoSeven® 35 or 70 mcg/kg at dosing intervals of 2 to 3 hours. Efficacy reflects the number of patients reporting excellent, effective, or partially effective results. Response was rated as “excellent” if patient demonstrated definitive relief of pain/tenderness and/or if there was a measurable decrease in the size of the bleed (or arrest of bleeding) in 8 hours or less. An “effective” response was measured by any of these 3 events occurring from 8 to 14 hours; a “partially effective” response either occurred after 14 hours or indicated detectable relief of pain/tenderness or decrease in size of the hemorrhage or if the bleeding had slowed.3
adept™2 phase 3 trial (Lentz, et al):
Data from an international, multicenter, randomized, double-blind, active controlled, confirmatory phase 3 trial of patients with hemophilia A or B with inhibitors (N=69). Primarily carried out in the home setting, all bleeds were treated, and each bleeding episode was randomized (3:2) to infuse either 1 to 3 doses of vatreptacog alfa (340 bleeding episodes, 80 mcg/kg) or 1 to 3 doses of NovoSeven® RT (227 bleeding episodes; 90 mcg/kg) when bleed symptoms were recognized, preferably within 2 hours of onset. Primary efficacy endpoint indicated effective bleed control defined as no additional hemostatic medication (other than the original medication) given within 12 hours after the initial dose.4
Randomized, double-blind bioequivalence trial (Bysted, et al):
Healthy participants (N=22) received 1 intravenous bolus injection each of NovoSeven® RT and NovoSeven®. Both bolus injections were 90 mcg/kg and occurred 2 to 3 weeks apart at consecutive visits. While the comparison is not shown for FVIIa, activity for NovoSeven® RT was the bioequivalent range of that for NovoSeven® during this period.6
Prospective, randomized trial evaluating efficacy in surgery (Shapiro, et al):
This trial compared 35 mcg/kg with 90 mcg/kg rFVIIa. Patients with inhibitors (FVIII, N=26; FIX, N=3) were given NovoSeven® RT immediately prior to incision, then every 2 hours intraoperatively or as needed, followed by every 2 hours from wound closure in the first 48 hours, then every 2 to 6 hours through day 5. Beyond day 5, patients were treated with open-label 90 mcg/kg until discharge of the investigator. A total of 29 patients underwent 11 major and 18 minor procedures. Data shown are from the 90 mcg/kg group.7
Explore how hospitals use NovoSeven® RT to treat CHwI.
Find the dose for your patients.*
*As a reminder, for US health care professionals only.
Find resources that can help your patients with inhibitors.
Selected Important Safety Information for NovoSeven® RT
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Warnings and Precautions
- Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
- Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
Indications and Usage
NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:
- Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
- Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia
Important Safety Information
WARNING: THROMBOSIS
- Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
- Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
- Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis
Warnings and Precautions
- Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
- Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
- Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
- Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
- Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis
Adverse Reactions
- The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia
Drug Interactions
- Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII
Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.
References
- NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020.
- SEVENFACT [package insert]. Louisville, KY: HEMA Biologics; 2020.
- Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798.
- Lentz SR, Ehrenforth S, Abdul Karim F, et al; adept™2 investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014;12(8):1244-1253.
- Neufeld EJ, Saxena K, Kessler CM, et al. Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008). Pediatr Blood Cancer. 2013;60(7):1178-1183.
- Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia. 2007;13(5):527-532.
- Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-778.
- FEIBA [package insert]. Westlake Village, CA: Baxalta US Inc; 2020.
- National Hemophilia Foundation. Recommendation on the use and management of emicizumab-kxwh (hemlibra®) for hemophilia a with and without inhibitors, #258. New York, NY: National Hemophilia Foundation; 2020.
- Levy GG, Asikanius E, Kuebler P, et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost. 2019;17(9):1470-1477.
- Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818 and appendix.
- National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders, #263. New York, NY: National Hemophilia Foundation; 2020.